Trial Profile
An Open-label, Uncontrolled, Single Arm Phase II Trial of Buparlisib in Patients With Metastatic Melanoma With Brain Metastases Not Eligible for Surgery or Radiosurgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- 06 Jun 2017 Prespecified activity goal (If there are one or fewer responses in the first 8 pts the study would stop.) for the first stage of accrual was met; currently 11/22 pts are enrolled.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 01 Apr 2015 New trial record